Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial.
Bühler, A
Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial. [electronic resource] - Blood cancer journal Mar 2016 - e404 p. digital
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
2044-5385
10.1038/bcj.2016.9 doi
Aged
Aged, 80 and over
Antineoplastic Agents--therapeutic use
Drug Resistance, Neoplasm
Female
Follow-Up Studies
Humans
Immunoglobulin Heavy Chains--genetics
Immunologic Factors--therapeutic use
Lenalidomide
Leukemia, Lymphocytic, Chronic, B-Cell--diagnosis
Male
Middle Aged
Mutation
Prognosis
Recurrence
Retreatment
Survival Analysis
Thalidomide--analogs & derivatives
Treatment Outcome
Tumor Suppressor Protein p53--genetics
Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial. [electronic resource] - Blood cancer journal Mar 2016 - e404 p. digital
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
2044-5385
10.1038/bcj.2016.9 doi
Aged
Aged, 80 and over
Antineoplastic Agents--therapeutic use
Drug Resistance, Neoplasm
Female
Follow-Up Studies
Humans
Immunoglobulin Heavy Chains--genetics
Immunologic Factors--therapeutic use
Lenalidomide
Leukemia, Lymphocytic, Chronic, B-Cell--diagnosis
Male
Middle Aged
Mutation
Prognosis
Recurrence
Retreatment
Survival Analysis
Thalidomide--analogs & derivatives
Treatment Outcome
Tumor Suppressor Protein p53--genetics